Chronic vestibular migraine (CVM) and cerebrovascular insufficiency are recognized contributors to cognitive impairment. Vestibular dysfunction affects spatial orientation and balance, while compromised cerebral perfusion impacts neuronal health. This study explores the combined pathological effects of these conditions and their role in cognitive decline and dementia. To evaluate the association between chronic vestibular migraine, cerebrovascular insufficiency, and their potential role in accelerating cognitive decline and the onset of dementia. A patient was evaluated from the ages of 48 to 74 years, initially diagnosed with chronic vestibular migraine and later developing cerebrovascular insufficiency. Cognitive function was assessed using the Mini-Mental State Examination (MMSE) over a 5-year follow-up. Neuroimaging, including MRI and CT angiography, was employed to assess cerebral perfusion and white matter changes. The incidence of dementia was evaluated based on the Diagnostic and Statistical Manual of Mental Disorders (DSM-5) criteria. The patient with coexisting CVM and cerebrovascular insufficiency demonstrated rapid cognitive decline, with MMSE scores decreasing by an average of 5 points over the follow-up period. Neuroimaging revealed microvascular ischemic changes and white matter lesions. Frequent vestibular migraines were associated with the progression to dementia over years of regular assessment and follow-up. Chronic vestibular migraine and cerebrovascular insufficiency are significantly associated with accelerated cognitive decline and an increased risk of dementia. The presence of white matter lesions and ischemic changes appears to exacerbate neurodegeneration. Early diagnosis and management of vestibular dysfunction and cerebrovascular risk factors may help mitigate cognitive decline and reduce the incidence of dementia in affected patients.
Download full-text PDF |
Source |
---|---|
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC11890893 | PMC |
http://dx.doi.org/10.1007/s12070-024-05200-x | DOI Listing |
Europace
March 2025
Clinical Cardiac Academic Group, Genetic and Cardiovascular Sciences Institute, City-St George's University of London, London, UK.
Atrial fibrillation (AF) is one of the most common cardiac diseases and a complicating comorbidity for multiple associated diseases. Many clinical decisions regarding AF are currently based on the binary recognition of AF being present or absent with the categorical appraisal of AF as continued or intermittent. Assessment of AF in clinical trials is largely limited to the time to (first) detection of an AF episode.
View Article and Find Full Text PDFClin Neuropharmacol
March 2025
Department of Neurology, Firoozgar Hospital, School of Medicine, Iran University of Medical Science, Fasa, Iran.
Objectives: People with diabetes are 1.5 times more likely to experience stroke than those without diabetes, underlining the urgent need to address this issue. Metformin is often the initial medication chosen to manage diabetes mellitus (DM).
View Article and Find Full Text PDFJAMA Netw Open
March 2025
Department of Neurology, Dell Medical School, The University of Texas at Austin.
Importance: Tenecteplase is an alternative to alteplase for emergency treatment of acute ischemic stroke. However, limited data are available comparing their clinical effectiveness in routine clinical practice.
Objective: To compare short-term effectiveness and safety outcomes for patients with ischemic stroke treated with intravenous tenecteplase vs alteplase.
Fabry disease (FD) is a lysosomal disorder due to alpha-galactosidase-A enzyme deficiency, accumulation of globotriaosylceramide (Gb3) and globotriaosylsphingosine (lyso-Gb3) which lead to proinflammatory effects. Males develop progressive hypertrophic cardiomyopathy (HCM) followed by fibrosis; females develop nonconcentric hypertrophy and/or early fibrosis. The inflammatory response to Gb3/lyso-Gb-3 accumulation is one of the suggested pathogenic mechanisms in FD cardiomyopathy when the secretion of inflammatory and transforming growth factors with infiltration of lymphocytes and macrophages into tissue promotes cardiofibrosis.
View Article and Find Full Text PDFACS Chem Neurosci
March 2025
Department of Pharmacology, University of Michigan, Ann Arbor, Michigan 48109, United States.
Bispecific antibodies (bAbs) that engage cerebrovascular targets, induce transport across the blood-brain barrier (BBB), and redistribute to secondary targets within the brain parenchyma have the potential to transform the diagnosis and treatment of a wide range of central nervous system disorders. Full understanding of the pharmacokinetics (PK) of these agents, including their potential for delivering cargo into brain parenchymal cells, is a key priority for the development of numerous potential therapeutic applications. To date, the brain PK of bAbs that target transferrin receptor (TfR-1) and CD98 heavy chain (CD98hc) has been characterized using techniques incapable of distinguishing between CNS clearance of intact protein from uptake and catabolism by brain parenchymal cells.
View Article and Find Full Text PDFEnter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!